Aaron Amacher, MD
Ophthalmology · Phoenix, AZNPI 1700856283
Payments from drug & device makers
What this record shows
This record is dominated by other: $3,179 of the $5,011 with a category attached, or 63.4%. Alcon accounts for 68.5% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2021 at $3,283 and has fallen 88.0% since, to $394 in 2025.
Across 62 payments — averaging $80.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$3K
- Rxsight Inc$608
- Johnson & Johnson Surgical Vision, Inc.$329
- Harrow Eye, LLC$215
- Novartis$73
- AbbVie$63
- plus $292 from 10 others
What the payments were for
- Speaking & faculty fees$261%
- Food & beverage$1,80736%
- Other$3,17963%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 8 | $3,431 |
| Rxsight Inc | 10 | $608 |
| Johnson & Johnson Surgical Vision, Inc. | 20 | $329 |
| Harrow Eye, LLC | 4 | $215 |
| Novartis | 4 | $73 |
| AbbVie(2 entities) | 3 | $63 |
| Bausch & Lomb Americas Inc. | 3 | $47 |
| Rayner Intraocular Lenses Limited | 2 | $40 |
| Carl Zeiss Meditec, Inc. | 1 | $36 |
| Genentech USA, Inc. | 1 | $34 |
| Apellis Pharmaceuticals, Inc. | 1 | $32 |
| Ocular Therapeutix, Inc. | 1 | $23 |
| Oyster Point Pharma, Inc. | 1 | $21 |
| Kala Pharmaceuticals, Inc. | 1 | $21 |
| Mallinckrodt Enterprises LLC | 1 | $20 |
| Biotissue Holdings Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,011 in reported general payments places this provider in the 80th percentile of 310 ophthalmology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 140 | $3,788 |
| Diclofenac Sodium | 84 | $814 |
| Ofloxacin | 24 | $261 |
| ErythromycinErythromycin Base | 20 | $201 |
| Brimonidine Tartrate | 15 | $79 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 19 | $72 |
| Temazepam | 13 | $27 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Phoenix
- Pravin DugelPhoenix$176K
- Nishi ShahPhoenix$92K
- Karim JamalPhoenix$72K
- Benjamin HellerPhoenix$41K
- Neal PalejwalaPhoenix$33K
- Joshua DuncanPhoenix$30K
- Sachin MehtaPhoenix$23K
- Daniel ChurginPhoenix$15K
- John CasonPhoenix$14K
- Sujit IttyPhoenix$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.